{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:01:09Z","timestamp":1760014869445},"reference-count":46,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0730","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:24:09Z","timestamp":1525253049000},"source":"Crossref","is-referenced-by-count":5,"title":["Screening and Treatment in Retinopathy of Prematurity"],"prefix":"10.3238","author":[{"given":"Andreas","family":"Stahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"G\u00f6pel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2015,10,23]]},"reference":[{"key":"10.3238\/arztebl.2015.0730_ref1","unstructured":"AQUA\u2013Institut f\u00fcr angewandte Qualit\u00e4tsf\u00f6rderung und Forschung im Gesundheitswesen: Bundesauswertung Neonatologie. 2014."},{"key":"10.3238\/arztebl.2015.0730_ref2","doi-asserted-by":"crossref","unstructured":"Hirneiss C, Neubauer AS, Tribus C, Kampik A: \u201eValue-based medicine\u201c in der Augenheilkunde. Ophthalmologe 2006; 103: 493\u2013500","DOI":"10.1007\/s00347-006-1340-9"},{"key":"10.3238\/arztebl.2015.0730_ref3","doi-asserted-by":"crossref","unstructured":"Dhaliwal CA, Fleck BW, Wright E, Graham C, McIntosh N: Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age. Arch Dis Child Fetal Neonatal Ed 2009; 94: F193\u20135","DOI":"10.1136\/adc.2008.143552"},{"key":"10.3238\/arztebl.2015.0730_ref4","doi-asserted-by":"crossref","unstructured":"Pelken L, Maier RF: Risikofaktoren und Pr\u00e4vention der Retinopathia praematurorum. Ophthalmologe 2008; 105: 1108\u201313","DOI":"10.1007\/s00347-008-1788-x"},{"key":"10.3238\/arztebl.2015.0730_ref5","doi-asserted-by":"crossref","unstructured":"Lofqvist C, Andersson E, Sigurdsson J, et al.: Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124: 1711\u20138","DOI":"10.1001\/archopht.124.12.1711"},{"key":"10.3238\/arztebl.2015.0730_ref6","doi-asserted-by":"crossref","unstructured":"van Sorge AJ, Termote JU, Kerkhoff FT, et al.: Nationwide inventory of risk factors for retinopathy of prematurity in the Netherlands. J Pediatr 2014; 164: 494\u20138 e1.","DOI":"10.1016\/j.jpeds.2013.11.015"},{"key":"10.3238\/arztebl.2015.0730_ref7","doi-asserted-by":"crossref","unstructured":"Wallace DK, Kylstra JA, Phillips SJ, Hall JG: Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS 2000; 4: 343\u20137","DOI":"10.1067\/mpa.2000.110342"},{"key":"10.3238\/arztebl.2015.0730_ref8","doi-asserted-by":"crossref","unstructured":"Ko CH, Kuo HK, Chen CC, et al.: Using WINROP as an adjuvant screening tool for retinopathy of prematurity in southern Taiwan. Am J Perinatol 2015; 30: 149\u201354","DOI":"10.1055\/s-0034-1376389"},{"key":"10.3238\/arztebl.2015.0730_ref9","doi-asserted-by":"crossref","unstructured":"Lofqvist C, Hansen-Pupp I, Andersson E, et al.: Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol 2009; 127: 622\u20137","DOI":"10.1001\/archophthalmol.2009.69"},{"key":"10.3238\/arztebl.2015.0730_ref10","doi-asserted-by":"crossref","unstructured":"Eriksson L, Liden U, Lofqvist C, Hellstrom A: WINROP can modify ROP screening praxis: a validation of WINROP in populations in Sormland and Vastmanland. Br J Ophthalmol 2014; 98: 964\u20136","DOI":"10.1136\/bjophthalmol-2013-304617"},{"key":"10.3238\/arztebl.2015.0730_ref11","doi-asserted-by":"crossref","unstructured":"Wu C, Vanderveen DK, Hellstrom A, Lofqvist C, Smith LE: Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol 2010; 128: 443\u20137","DOI":"10.1001\/archophthalmol.2010.31"},{"key":"10.3238\/arztebl.2015.0730_ref12","doi-asserted-by":"crossref","unstructured":"Hellstrom A, Carlsson B, Niklasson A, et al.: IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002; 87: 3413\u20136","DOI":"10.1210\/jc.87.7.3413"},{"key":"10.3238\/arztebl.2015.0730_ref13","doi-asserted-by":"crossref","unstructured":"Hellstrom A, Engstrom E, Hard AL, et al.: Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112: 1016\u201320","DOI":"10.1542\/peds.112.5.1016"},{"key":"10.3238\/arztebl.2015.0730_ref14","doi-asserted-by":"crossref","unstructured":"Singer D, Muhlfeld C: Perinatal adaptation in mammals: the impact of metabolic rate. Comp Biochem Physiol A Mol Integr Physiol 2007; 148: 780\u20134","DOI":"10.1016\/j.cbpa.2007.05.004"},{"key":"10.3238\/arztebl.2015.0730_ref15","doi-asserted-by":"crossref","unstructured":"Gerhardt H, Golding M, Fruttiger M, et al.: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163\u201377","DOI":"10.1083\/jcb.200302047"},{"key":"10.3238\/arztebl.2015.0730_ref16","doi-asserted-by":"crossref","unstructured":"Chen J, Stahl A, Hellstrom A, Smith LE: Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr 2010; 23: 173\u20138","DOI":"10.1097\/MOP.0b013e3283423f35"},{"key":"10.3238\/arztebl.2015.0730_ref17","doi-asserted-by":"crossref","unstructured":"Mantagos IS, Vanderveen DK, Smith LE: Emerging treatments for retinopathy of prematurity. Semin Ophthalmol 2009; 24: 82\u20136","DOI":"10.1080\/08820530902800322"},{"key":"10.3238\/arztebl.2015.0730_ref18","doi-asserted-by":"crossref","unstructured":"Sonmez K, Drenser KA, Capone A Jr., Trese MT: Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115: 1065\u201370 e1.","DOI":"10.1016\/j.ophtha.2007.08.050"},{"key":"10.3238\/arztebl.2015.0730_ref19","doi-asserted-by":"crossref","unstructured":"Velez-Montoya R, Clapp C, Rivera JC, et al.: Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity. Clin Ophthalmol 2010; 4: 947\u201353","DOI":"10.2147\/OPTH.S11650"},{"key":"10.3238\/arztebl.2015.0730_ref20","doi-asserted-by":"crossref","unstructured":"STOP-ROP-Group: Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105: 295\u2013310","DOI":"10.1542\/peds.105.2.295"},{"key":"10.3238\/arztebl.2015.0730_ref21","doi-asserted-by":"crossref","unstructured":"Jandeck C, Kellner U, Lorenz B, Seiberth V: Leitlinie zur augen\u00e4rztlichen Screening-Untersuchung von Fr\u00fchgeborenen. Klin Monbl Augenheilkd 2008; 225: 123\u201330","DOI":"10.1055\/s-2008-1027168"},{"key":"10.3238\/arztebl.2015.0730_ref22","doi-asserted-by":"crossref","unstructured":"Wang SK, Callaway NF, Wallenstein MB, Henderson MT, Leng T, Moshfeghi DM: SUNDROP: six years of screening for retinopathy of prematurity with telemedicine. Can J Ophthalmol 2015; 50: 101\u20136","DOI":"10.1016\/j.jcjo.2014.11.005"},{"key":"10.3238\/arztebl.2015.0730_ref23","doi-asserted-by":"crossref","unstructured":"Vander JF, Handa J, McNamara JA, et al.: Early treatment of posterior retinopathy of prematurity: a controlled trial. Ophthalmology 1997; 104: 1731\u20135; discussion 5\u20136.","DOI":"10.1016\/S0161-6420(97)30034-7"},{"key":"10.3238\/arztebl.2015.0730_ref24","doi-asserted-by":"crossref","unstructured":"Davitt BV, Dobson V, Good WV, et al.: Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology 2005; 112: 1564\u20138","DOI":"10.1016\/j.ophtha.2005.03.025"},{"key":"10.3238\/arztebl.2015.0730_ref25","doi-asserted-by":"crossref","unstructured":"Holmstrom GE, Hellstrom A, Jakobsson PG, Lundgren P, Tornqvist K, Wallin A: Swedish national register for retinopathy of prematurity (SWEDROP) and the evaluation of screening in Sweden. Arch Ophthalmol 2012; 130: 1418\u201324","DOI":"10.1001\/archophthalmol.2012.2357"},{"key":"10.3238\/arztebl.2015.0730_ref26","doi-asserted-by":"crossref","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR: Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-Year retrospective analysis. Ophthalmology 2015; 122: 1008\u201315","DOI":"10.1016\/j.ophtha.2014.12.017"},{"key":"10.3238\/arztebl.2015.0730_ref27","doi-asserted-by":"crossref","unstructured":"Geloneck MM, Chuang AZ, Clark WL, et al.: Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial. JAMA Ophthalmol 2014; 132: 1327\u201333","DOI":"10.1001\/jamaophthalmol.2014.2772"},{"key":"10.3238\/arztebl.2015.0730_ref28","doi-asserted-by":"crossref","unstructured":"Yang CS, Wang AG, Sung CS, Hsu WM, Lee FL, Lee SM: Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: a study of refractive status at 7 years. Eye (Lond) 2010; 24: 14\u201320","DOI":"10.1038\/eye.2009.63"},{"key":"10.3238\/arztebl.2015.0730_ref29","doi-asserted-by":"crossref","unstructured":"Brown DM, Kaiser PK, Michels M, et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432\u201344","DOI":"10.1056\/NEJMoa062655"},{"key":"10.3238\/arztebl.2015.0730_ref30","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419\u201331","DOI":"10.1056\/NEJMoa054481"},{"key":"10.3238\/arztebl.2015.0730_ref31","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331\u20135","DOI":"10.3928\/1542-8877-20050701-14"},{"key":"10.3238\/arztebl.2015.0730_ref32","doi-asserted-by":"crossref","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ: Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1727\u201330","DOI":"10.1007\/s00417-007-0661-y"},{"key":"10.3238\/arztebl.2015.0730_ref33","doi-asserted-by":"crossref","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897\u2013908","DOI":"10.1056\/NEJMoa1102673"},{"key":"10.3238\/arztebl.2015.0730_ref34","doi-asserted-by":"crossref","unstructured":"Joussen AM, Bornfeld N: The treatment of wet age-related macular degeneration. Dtsch Arztebl Int 2009; 106: 312\u20137","DOI":"10.3238\/arztebl.2009.0312"},{"key":"10.3238\/arztebl.2015.0730_ref35","doi-asserted-by":"crossref","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603\u201315","DOI":"10.1056\/NEJMoa1007374"},{"key":"10.3238\/arztebl.2015.0730_ref36","doi-asserted-by":"crossref","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R: Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; 130: 1000\u20136","DOI":"10.1001\/archophthalmol.2012.592"},{"key":"10.3238\/arztebl.2015.0730_ref37","doi-asserted-by":"crossref","unstructured":"Lee BJ, Kim JH, Heo H, Yu YS: Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye (Lond) 2012; 26: 903\u20139; quiz 10","DOI":"10.1038\/eye.2012.111"},{"key":"10.3238\/arztebl.2015.0730_ref38","doi-asserted-by":"crossref","unstructured":"Pertl L, Steinwender G, Mayer C, et al.: A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 2015; 10: e0129383","DOI":"10.1371\/journal.pone.0129383"},{"key":"10.3238\/arztebl.2015.0730_ref39","doi-asserted-by":"crossref","unstructured":"Fierson WM: Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131: 189\u201395","DOI":"10.1542\/peds.2012-2996"},{"key":"10.3238\/arztebl.2015.0730_ref40","doi-asserted-by":"crossref","unstructured":"Redaktionskomitee von DOG BVA und RG: Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augen\u00e4rzte Deutschlands zum Einsatz von Bevacizumab in der Therapie der Fr\u00fchgeborenenretinopathie. Ophthalmologe 2012; 109: 197\u2013204.","DOI":"10.1007\/s00347-011-2519-2"},{"key":"10.3238\/arztebl.2015.0730_ref41","doi-asserted-by":"crossref","unstructured":"Barth T, Hufendiek K, Helbig H, Oberacher-Velten I: Laserbehandlung oder intravitreale VEGF-Inhibition bei aggressiver Fr\u00fchgeborenenretinopathie? Ophthalmologe 2015; 112: 520\u201324.","DOI":"10.1007\/s00347-014-3172-3"},{"key":"10.3238\/arztebl.2015.0730_ref42","doi-asserted-by":"crossref","unstructured":"Isaac M, Mireskandari K, Tehrani N: Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS 2015; 19: 140\u20134","DOI":"10.1016\/j.jaapos.2015.01.009"},{"key":"10.3238\/arztebl.2015.0730_ref43","doi-asserted-by":"crossref","unstructured":"Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, et al.: Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 2013; 33: 329\u201338.","DOI":"10.1097\/IAE.0b013e318275394a"},{"key":"10.3238\/arztebl.2015.0730_ref44","doi-asserted-by":"crossref","unstructured":"Geloneck MM, Chuang AZ, Clark WL, et al.: Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014; 132: 1327\u201333","DOI":"10.1001\/jamaophthalmol.2014.2772"},{"key":"10.3238\/arztebl.2015.0730_ref45","doi-asserted-by":"crossref","unstructured":"Chen YH, Chen SN, Lien RI, et al.: Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond) 2014; 28: 1080\u20136; quiz 7.","DOI":"10.1038\/eye.2014.172"},{"key":"10.3238\/arztebl.2015.0730_ref46","doi-asserted-by":"crossref","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB: Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013; 155: 1119\u201324 e1.","DOI":"10.1016\/j.ajo.2013.01.014"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T14:06:11Z","timestamp":1638799571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,23]]},"references-count":46,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0730","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,23]]}}}